Background and rationale
Chronic pain is the most feared symptom in palliative care (PC) patients. While paracetamol is effective for mild to moderate pain and useful when used in combination with "weak opioids," it is not certain that there is sufficient continuing benefit when used in conjunction with "strong" opioids for moderate to severe pain to justify the additional medication burden.
Although there have been several studies describing opioid-sparing effects of paracetamol, there have been only a handful in patients with advanced cancer and pain despite strong opioids. A 2013 critical review concluded that the role of paracetamol in management of cancer pain remains controversial. 1 We conducted a series of n-of-1 trials to test the feasibility of using this methodology to obtain the per patient effectiveness of paracetamol in providing additional analgesia to regular opioids in people with advanced cancer experiencing moderate to severe pain. Single-patient multiple crossover studies to determine the effectiveness of paracetamol in relieving pain suffered by patients with advanced cancer taking regular opioids: A pilot study Jane Nikles 1 , Geoffrey K Mitchell 1 , Janet Hardy 2 , Hugh Senior 3 , Sue-Ann Carmont 1 , Philip J Schluter 4,5 , Rohan Vora 6 , David Currow 7 and Michael Yelland 8
What is already known about the topic?
• • Paracetamol is a useful adjunct when used in combination with "weak opioids" for chronic pain in palliative care patients with advanced cancer; however, it is not certain that there is continuing benefit when used in conjunction with "strong" opioids.
What this paper adds?
• • N-of-1 trials allowed individual treatment decisions to be made for each participant: there was no added benefit for any of the participants, although no conclusion about the added benefit of paracetamol above regular opioids was possible for the group, due to insufficient numbers recruited.
Implications for practice, theory, or policy
• • Paracetamol may not provide added benefit above regular opioids; this should be assessed on a case-by-case basis to justify the extra tablet load.
Methods

Design
We conducted double-blind, placebo-controlled three-cycle multiple crossover n-of-1 trials in individual patients. Each cycle was 6 days, comprising two 3-day treatment periods of slow release paracetamol 665 mg tabs (GlaxoSmithKline; over-encapsulated), or identical placebo, two capsules three times per day. Data from the first day of each 3-day period were discarded. The order of drugs in each cycle was determined by a random allocation schedule with block size of four, set prior to commencement of recruitment. Allocation was blinded to clinician, investigator, and patient. Patient-completed daily diaries recorded Brief Pain Inventory (BPI) scores. 2 The trial result was compared to a predetermined clinically important change of 2.0 from baseline in BPI pain on average score over the last 24 h. 3 Individual patient reports were generated to allow consultation between participant and clinician to decide whether to continue paracetamol.
Study population
Patients with advanced cancer taking opioids for moderate to severe chronic pain, in Queensland, Australia, from May 2010 to September 2012.
Approvals were obtained from Institutional Review Boards (IRBs) of participating hospitals, and the University of Queensland. All patients provided written informed consent. 
Inclusion criteria
Results
Overall, seven participants commenced, with three completing three cycles, one completing two cycles, one completing one cycle, and two not completing any cycles.
Individual patients' mean differences in BPI Pain on average between paracetamol and placebo ranged from 0.2 to 0.3 with no patient having an important positive or negative response. Addition of paracetamol gave no added benefit above placebo. For three patients, paracetamol provided small additional pain relief in secondary outcomes, but this was not clinically significant.
Adverse events
There were two grade 1 adverse events (irregular heart beat) and three grade 2 adverse events (constipation), unrelated to paracetamol. There were no reported serious adverse events.
Discussion
Taking paracetamol in addition to opioids did not outweigh the additional tablet burden for any of the patients.
We demonstrated the considerable advantage of participating in n-of-1 trials over randomized controlled trials (RCTs), namely, participation gave useful evidence for every participant who completed at least one cycle.
Recruitment was more difficult than expected. Barriers to recruitment were not related to the n-of-1 trial design, but to the strict inclusion criteria, including the need to have been on a stable opioid dose. Many potential participants had far advanced disease and pain control requiring frequent medication adjustments thereby excluding them from participating. The extent of this problem was not fully anticipated and resulted in only seven eligible participants being recruited. There were also other problematic issues including the time taken to obtain ethics and governance approval for each site. A decision was made not to proceed to a full trial in this patient population. For future research in this area, we recommend targeting community patients earlier in the cancer trajectory, with less stringent eligibility criteria.
